Loading
YL201 is an experimental antibody-drug conjugate from MediLink Therapeutics (Suzhou) in phase 3 trials for nasopharyngeal carcinoma, non-small-cell lung cancer and small-cell lung cancer, aimed at B7-H3.
YL201 is an antibody-drug conjugate developed by MediLink Therapeutics (Suzhou). Its target is B7-H3 (the sponsor names B7-H3). ClinicalTrials.gov describes the intervention as: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle. It is the investigational product in 9 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06629597 (A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)), NCT06612151 (A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）) and NCT07739758 (A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer), in nasopharyngeal carcinoma, non-small-cell lung cancer, small-cell lung cancer and prostate cancer. The largest, NCT06057922, plans to enrol 990 participants with primary completion expected 2026-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Antibody-drug conjugate directed at B7-H3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to B7-H3.
1.YL201's antibody arm binds B7-H3 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"YL201" OR ABSTRACT:"YL201" OR TITLE:"Tam-Peli" OR ABSTRACT:"Tam-Peli" OR TITLE:"Tambotatug Pelitecan" OR ABSTRACT:"Tambotatug Pelitecan") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about YL201, not a curated reading list.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma and the tag pipeline.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma and the tag pipeline.
Shares MediLink Therapeutics, Non-small-cell lung cancer and the tag pipeline.
Shares B7-H3, Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma and the tag pipeline.